Table 2.
Comparative assessment of budesonide‐MMX and mesalamine in active, mild‐to‐moderate UC
| A. Induction of clinical and endoscopic remission | |||
|---|---|---|---|
| Budesonide‐MMX | |||
| 0.97 (0.59–1.60) | Mesalamine >2.4 g/day | ||
| 1.23 (0.76–2.01) | 1.27 (1.03–1.56) | Mesalamine 1.6–2.4 g/day | |
| 2.68 (1.75–4.10) | 2.75 (1.94–3.90) | 2.17 (1.55–3.05) | Placebo |
| B. Serious adverse events | |||
|---|---|---|---|
| Budesonide‐MMX | |||
| 1.85 (0.59–5.79) | Mesalamine >2.4 g/day | ||
| 1.44 (0.52–3.97) | 0.78 (0.40–1.51) | Mesalamine 1.6–2.4 g/day | |
| 1.35 (0.60–3.04) | 0.73 (0.29–1.82) | 0.94 (0.43–2.04) | Placebo |
| C. Treatment discontinuations or withdrawals from the study due to adverse events | |||
|---|---|---|---|
| Budesonide‐MMX | |||
| 2.22 (1.23–4.02) | Mesalamine >2.4 g/day | ||
| 1.71 (0.98–2.96) | 0.77 (0.52–1.14) | Mesalamine 1.6–2.4 g/day | |
| 0.92 (0.61–1.38) | 0.41 (0.26–0.66) | 0.54 (0.34–0.84) | Placebo |
The column‐defining treatment is compared with the row‐defining treatment. The estimates in the cells are odds ratios (ORs) with 95% confidence intervals. For induction of clinical and endoscopic remission, ORs >1.0 favour the treatment in the left upper square. On the opposite, for safety outcomes (serious adverse events and withdrawals from the study due to adverse events), ORs <1.0 favour the treatment in the left upper square. Statistically significant results are shown in bold.
UC, ulcerative colitis.